UOC, Ematologia Azienda Ospedaliero Universitaria Arcispedale S. Anna Trials

UOC, Ematologia Azienda Ospedaliero Universitaria Arcispedale S. Anna	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Cuneo, Antonio

SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Terminated

246

Europe, Canada, US, RoW

Tamibarotene, SY-1425, Placebo, Azacitidine

Syros Pharmaceuticals

Myelodysplastic Syndromes

11/24

BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting

600

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

04/26

01/27

CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting

897

Europe, RoW

Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro

German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG), Janssen Pharmaceutica N.V., Belgium, AbbVie, Hoffmann-La Roche

Chronic Lymphoid Leukemia

09/27

FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting

602

Europe

Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

07/28

07/30

CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide

Terminated

Europe

Rituximab, Chemotherapy, Tenofovir alafenamide

Gruppo Italiano Malattie EMatologiche dell'Adulto

Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia

05/24

DREAMM 14, NCT05064358 / 2021-004151-16: Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

Jul 2024 - Dec 2024 : Data for RRMM

Active, not recruiting

177

Europe, Canada, US, RoW

Belantamab mafodotin

GlaxoSmithKline

Multiple Myeloma

08/24

01/26

NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting

249

Europe, Canada, US, RoW

Pirtobrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

06/28

12/28

AL-TOMICA, NCT06626893: Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention

Recruiting

N/A

100

Europe

Functional tests, Next Generation Sequencing analysis, Microvesicles analysis

Azienda Ospedaliero-Universitaria di Parma

Myeloid Leukemia, Acute, Leukemia, Acute Lymphoblastic

03/25

NCT06506084: Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)

Recruiting

N/A

319

Europe

Ropeginterferon alfa-2b, Besremi

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Polycythemia Vera

09/26

12/26

NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting

N/A

250

Europe

Ospedale di Circolo - Fondazione Macchi

SARS-CoV-2 Infection, Hematological Malignancies

10/22

CML1012, NCT01752062: Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors

Recruiting

N/A

148

Europe

Gruppo Italiano Malattie EMatologiche dell'Adulto

Chronic Myeloid Leukemia, Pregnancy

12/22

SilOs, NCT06720870: An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context

Recruiting

N/A

Europe

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Castleman Disease

01/25

CLL2423, NCT05803395: Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

Recruiting

N/A

954

Europe

Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione Italiana Linfomi

Chronic Lymphocytic Leukemia, Indolent B-Cell Non-Hodgkin Lymphoma, COVID-19

09/24

NCT05393024: Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy

Completed

N/A

Europe

Belantamab mafodotin

Fondazione EMN Italy Onlus

Multiple Myeloma

08/24

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Cuneo, Antonio

SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Terminated

246

Europe, Canada, US, RoW

Tamibarotene, SY-1425, Placebo, Azacitidine

Syros Pharmaceuticals

Myelodysplastic Syndromes

11/24

Active, not recruiting

600

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

04/26

01/27

Active, not recruiting

897

Europe, RoW

Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro

Chronic Lymphoid Leukemia

09/27

FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting

602

Europe

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

07/28

07/30

Terminated

Europe

Rituximab, Chemotherapy, Tenofovir alafenamide

Gruppo Italiano Malattie EMatologiche dell'Adulto

Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia

05/24

DREAMM 14, NCT05064358 / 2021-004151-16: Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

Jul 2024 - Dec 2024 : Data for RRMM

Active, not recruiting

177

Europe, Canada, US, RoW

Belantamab mafodotin

GlaxoSmithKline

Multiple Myeloma

08/24

01/26

NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting

249

Europe, Canada, US, RoW

Pirtobrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

06/28

12/28

AL-TOMICA, NCT06626893: Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention

Recruiting

N/A

100

Europe

Functional tests, Next Generation Sequencing analysis, Microvesicles analysis

Azienda Ospedaliero-Universitaria di Parma

Myeloid Leukemia, Acute, Leukemia, Acute Lymphoblastic

03/25

NCT06506084: Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)

Recruiting

N/A

319

Europe

Ropeginterferon alfa-2b, Besremi

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Polycythemia Vera

09/26

12/26

NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting

N/A

250

Europe

Ospedale di Circolo - Fondazione Macchi

SARS-CoV-2 Infection, Hematological Malignancies

10/22

CML1012, NCT01752062: Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors

Recruiting

N/A

148

Europe

Gruppo Italiano Malattie EMatologiche dell'Adulto

Chronic Myeloid Leukemia, Pregnancy

12/22

Recruiting

N/A

Europe

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Castleman Disease

01/25

CLL2423, NCT05803395: Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

Recruiting

N/A

954

Europe

Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione Italiana Linfomi

Chronic Lymphocytic Leukemia, Indolent B-Cell Non-Hodgkin Lymphoma, COVID-19

09/24

NCT05393024: Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy

Completed

N/A

Europe

Belantamab mafodotin

Fondazione EMN Italy Onlus

Multiple Myeloma

08/24



	Diseases Companies Products Productz Mechanisms of Action Sites